Two separate FDA approvals made 2026 the year of the GLP-1 pill. Novo Nordisk's Wegovy pill (oral semaglutide 25 mg) became the first oral GLP-1 approved for chronic weight management and reached U.S. pharmacies in early January 2026. Eli Lilly followed on April 1, 2026, when the FDA approved Foundayo (orforglipron), the first GLP-1 pill that can be taken at any time of day with no food or water restrictions.

Both medications work the same way their injectable cousins do: they mimic GLP-1, a gut hormone that suppresses appetite, slows stomach emptying, and helps regulate blood sugar. The difference is purely the delivery — a daily tablet instead of a weekly shot.

The Wegovy pill contains semaglutide, the same active ingredient as injectable Wegovy and Ozempic, titrated up to a 25 mg once-daily dose.

Results. In the OASIS 4 trial, participants taking oral semaglutide lost an average of 13.6% of their body weight versus 2.4% with placebo — and those who stayed on treatment as prescribed lost close to 17%, results in the same range as the weekly injection.

How you take it. This is the pill's one real catch: semaglutide is fragile in the gut, so the tablet must be taken on an empty stomach when you wake up, with a small sip of water, followed by a 30-minute wait before eating, drinking, or taking other medications.

Cost. Novo launched the pill at $149 per month for starter doses for cash-paying patients, rising to $199–$299 per month at higher maintenance doses. Insured patients may pay as little as $25 per month with a savings card.

Foundayo is different chemistry: a small-molecule GLP-1 receptor agonist rather than a peptide. That sounds academic, but it has a practical payoff — the tablet is absorbed normally, so there are no timing, food, or water rules at all.

Results. In the ATTAIN-1 trial of more than 3,100 adults, the highest dose produced an average weight loss of 27.3 pounds (12.4% of body weight) over 72 weeks versus 0.9% with placebo. Participants also improved waist circumference, blood pressure, triglycerides, and non-HDL cholesterol.

How you take it. One tablet, once a day, any time — with or without food. Doses range from 0.8 mg up to 17.2 mg, titrated gradually to limit stomach side effects.

Cost. Lilly priced self-pay Foundayo starting at $149 per month, with commercial-insurance patients paying as little as $25 per month and a $50 per month Medicare Part D option that took effect July 1, 2026.

The honest answer: injections still lead on raw efficacy. Weekly semaglutide 2.4 mg averages about 15% body-weight loss, and tirzepatide has topped 20% in trials. If maximum weight loss is the goal and needles don't bother you, an injectable like tirzepatide remains the strongest tool available.

But the best medication is the one you'll actually take consistently. A daily pill wins if you're needle-averse, travel often and don't want to manage refrigerated pens, or simply prefer a routine that looks like taking a vitamin. Between the two pills, the trade-off is convenience versus track record: Foundayo has the friendliest dosing rules, while the Wegovy pill offers semaglutide's longer real-world history — with a strict morning fasting routine attached.

Side effects are similar across all GLP-1s: nausea, constipation, diarrhea, and heartburn are the most common, especially during dose increases. Like other GLP-1 medications, both pills carry a boxed warning about thyroid C-cell tumors seen in rodent studies, and neither is appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN 2. A licensed provider will screen for these and other contraindications before prescribing.

You don't need to figure this out alone, and you don't need a month-long wait for a specialist appointment. Through JoeyMed's weight loss program, a licensed provider reviews your health history, weight loss goals, and preferences, then recommends the treatment that fits — whether that's a GLP-1 pill, a weekly injectable, or supportive care like anti-nausea medication to make titration easier.

2026 removed the biggest barrier to GLP-1 treatment for millions of people. If the needle was what stopped you, the conversation just got a lot easier to start.